Table 1.

Baseline characteristics.

	Overall (N=18)
Age
Mean (SD)	49.9 (13.6)
Median [Min, Max]	50.0 [27.0, 72.0]
Gender
Female	10 (55.6%)
Male	8 (44.4%)
Race
Black	1 (5.6%)
White	17 (94.4%)
Type of MS
PPMS	3 (16.7%)
RRMS	15 (83.3%)
Med
Ocrelizumab (OCR)	17 (94.4%)
Ofatumumab (OFA)	1 (5.6%)
Onset of Disease (years)
Mean (SD)	12.1 (9.02)
Median [Min, Max]	10.0 [3.00, 40.0]
Lymph <1.2
Mean (SD)	1.55 (0.620)
Median [Min, Max]	1.45 [0.600, 2.70]
Time from infusion (m)
Mean (SD)	4.32 (2.49)
Median [Min, Max]	4.00 [0.500, 11.0]
Missing	1 (5.6%)
time from injection (d)
Mean (SD)	22.1 (7.78)
Median [Min, Max]	18.0 [14.0, 38.0]
Vaccine
Moderna	5 (27.8%)
Pfizer	13 (72.2%)
Boosted
No	1 (5.6%)
Yes	17 (94.4%)